Cartesian Therapeutics, Inc.
RNAC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001453687
No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q2 2026, worth $90.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +12 vs. previous quarter
- 94
- 13F valueReported value at the end of Q2 2026
- $90.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RNAC, Q2 2026
No superinvestor reported holding RNAC at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Cartesian Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Brunn CarstenPresident and CEO | SSale | −23.8K | $6.82 | −$162.1K | −6.8%323.5K after | |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Miljkovic MilosChief Medical Officer | SSale | −3.57K | $6.82 | −$24.4K | −5.7%58.8K after | |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Davis BlaineChief Financial Officer | SSale | −10.6K | $6.82 | −$72.2K | −8.0%121.2K after | |
| Dec 8, 2025 (view filing) | Dec 4 | 4 days | Barabe Timothy CDirector | PPurchase | +30.0K | $6.86 | +$205.8K | +123.1%54.4K after | |
| Apr 11, 2025 (view filing) | Apr 9-11 | 2 days | Springer Timothy ADirector, 10% Owner | PPurchase | +22.4K | $10.21 | +$228.3K | +0.3%8.64M after | 5 lots |
| Apr 11, 2025 (view filing) | Apr 9-11 | 2 days | Springer Timothy ADirector, 10% Owner | PPurchase | +126.7K | $10.21 | +$1.29M | +23.9%656.5K after | 5 lots |
| Mar 20, 2025 (view filing) | Mar 18-20 | 2 days | Springer Timothy ADirector, 10% Owner | PPurchase | +89.9K | $15.26 | +$1.37M | +1.1%8.62M after | 3 lots |
| Jan 15, 2025 (view filing) | Jan 13-14 | 2 days | Springer Timothy ADirector, 10% Owner | PPurchase | +21.0K | $17.47 | +$366.4K | +0.2%8.53M after | 3 lots |
| Jan 7, 2025 (view filing) | Jan 3-6 | 4 days | Kurtoglu MetinChief Technology Officer | SSale | −4.88K | $16.78 | −$81.8K | −7.3%62.3K after | 2 lots |
| Jan 7, 2025 (view filing) | Jan 3-6 | 4 days | Miljkovic MilosChief Medical Officer | SSale | −1.88K | $16.78 | −$31.5K | −5.0%35.4K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Cartesian Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Squarepoint Ops LLC | 2,254,619 | $23.5M | 0.05% | +16,133+0.7% | Added |
| BlackRock, Inc. | 819,239 | $8.54M | 0.00% | +220,131+36.7% | Added |
| 683 Capital Management, LLC | 650,000 | $6.77M | 0.62% | +320,000+97.0% | Added |
| Vanguard Capital Management LLC | 555,823 | $5.79M | 0.00% | +148,226+36.4% | Added |
| FMR LLC | 368,429 | $3.84M | 0.00% | −431,314−53.9% | Reduced |
| Geode Capital Management, LLC | 356,525 | $3.72M | 0.00% | +92,831+35.2% | Added |
| AQR Capital Management LLC | 356,456 | $3.71M | 0.00% | +272,436+324.3% | Added |
| Millennium Management LLC | 309,887 | $3.23M | 0.00% | +25,570+9.0% | Added |
| Two Sigma Investments, LP | 296,293 | $3.09M | 0.00% | +128,980+77.1% | Added |
| State Street Corp | 249,212 | $2.60M | 0.00% | +48,875+24.4% | Added |